GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Cyclically Adjusted PS Ratio

SCYNEXIS (LTS:0L49) Cyclically Adjusted PS Ratio : 3.11 (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Cyclically Adjusted PS Ratio?

As of today (2024-05-28), SCYNEXIS's current share price is $2.33. SCYNEXIS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.75. SCYNEXIS's Cyclically Adjusted PS Ratio for today is 3.11.

The historical rank and industry rank for SCYNEXIS's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0L49' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.3   Max: 3.69
Current: 3.14

During the past years, SCYNEXIS's highest Cyclically Adjusted PS Ratio was 3.69. The lowest was 0.07. And the median was 0.30.

LTS:0L49's Cyclically Adjusted PS Ratio is ranked worse than
65.73% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs LTS:0L49: 3.14

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

SCYNEXIS's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.028. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


SCYNEXIS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for SCYNEXIS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Cyclically Adjusted PS Ratio Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.09 1.39

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.31 0.43 1.39 1.96

Competitive Comparison of SCYNEXIS's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Cyclically Adjusted PS Ratio falls into.



SCYNEXIS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

SCYNEXIS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.33/0.75
=3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SCYNEXIS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, SCYNEXIS's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.028/131.7762*131.7762
=0.028

Current CPI (Mar. 2024) = 131.7762.

SCYNEXIS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.119 100.560 0.156
201409 0.072 100.428 0.094
201412 1.206 99.070 1.604
201503 0.076 99.621 0.101
201506 0.052 100.684 0.068
201509 0.046 100.392 0.060
201512 0.046 99.792 0.061
201603 0.046 100.470 0.060
201606 0.044 101.688 0.057
201609 0.027 101.861 0.035
201612 0.027 101.863 0.035
201703 0.025 102.862 0.032
201706 0.025 103.349 0.032
201709 0.024 104.136 0.030
201712 0.022 104.011 0.028
201803 0.019 105.290 0.024
201806 0.014 106.317 0.017
201809 0.014 106.507 0.017
201812 0.013 105.998 0.016
201903 0.013 107.251 0.016
201906 0.011 108.070 0.013
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.454 111.754 0.535
202106 0.000 114.631 0.000
202109 0.019 115.734 0.022
202112 0.022 117.630 0.025
202203 0.021 121.301 0.023
202206 0.031 125.017 0.033
202209 0.033 125.227 0.035
202212 0.032 125.222 0.034
202303 0.024 127.348 0.025
202306 2.633 128.729 2.695
202309 0.037 129.860 0.038
202312 0.121 129.419 0.123
202403 0.028 131.776 0.028

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SCYNEXIS  (LTS:0L49) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


SCYNEXIS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines